Stocktoria

Werewolf Therapeutics, Inc. HOWL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-04-30

Werewolf Therapeutics, Inc. financials (annual)

Revenue
202020212022202320242025
Net income
-$15.0M -$50.0M -$53.8M -$37.4M -$70.5M -$60.8M 202020212022202320242025
Free cash flow
-$19.2M -$43.4M -$44.2M -$33.4M -$56.4M -$60.3M 202020212022202320242025

Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020
R&D expense$44.8M$56.4M$41.8M$53.8M$35.3M$16.6M
Operating income-$60.7M-$73.6M-$40.5M-$56.1M-$50.1M-$22.4M
Interest expense$3.1M$0
Income tax$0
Net income-$60.8M-$70.5M-$37.4M-$53.8M-$50.0M-$15.0M
EPS (diluted)$-1.33$-1.63$-1.05$-1.86$-10.94$-28.08
Operating cash flow-$60.3M-$56.2M-$32.6M-$40.6M-$42.9M-$18.6M
Free cash flow-$60.3M-$56.4M-$33.4M-$44.2M-$43.4M-$19.2M
Cash & equivalents$57.0M$111.0M$134.3M$129.3M$157.5M$92.6M
Total assets$69.4M$126.9M$174.8M$160.2M$179.2M$96.4M
Total liabilities$44.6M$53.5M$63.5M$37.9M$26.5M$7.2M
Shareholders' equity$24.8M$73.4M$111.4M$122.3M$152.8M-$51.9M

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.